申请人:Luo Guanglin
公开号:US20090258866A1
公开(公告)日:2009-10-15
The disclosure generally relates to the novel compounds of formula I, including their salts, which are CGRP receptor antagonists. The disclosure also relates to pharmaceutical compositions and methods for using the compounds in the treatment of CGRP related disorders including migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases such as asthma, and chronic obstructive pulmonary disease (COPD).
本公开通常涉及公式I的新化合物,包括它们的盐,这些盐是CGRP受体拮抗剂。本公开还涉及用于治疗CGRP相关疾病,包括偏头痛和其他头痛、神经源性血管扩张、神经源性炎症、热损伤、循环性休克、与更年期相关的潮红、气道炎症性疾病如哮喘和慢性阻塞性肺病(COPD)的药物组合物和方法。